BSW
REGN icon

Buckingham Strategic Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Buckingham Strategic Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,286
Closed -$2.09M – 460
2020
Q1 		$2.09M Buy
+4,286
New +$1.77M 0.2% 92

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Buckingham Strategic Wealth's REGN Position: Q2 2020 in Review

Buckingham Strategic Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 4,286 shares — an estimated $2.09M sold.

Buckingham Strategic Wealth first reported a position in REGN in Q1 2020 and held it in 1 quarter. The position peaked at $2.09M in Q1 2020. 932 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

  • Buckingham Strategic Wealth reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Buckingham Strategic Wealth sold 4,286 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $2.09M.
  • Buckingham Strategic Wealth first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Buckingham Strategic Wealth's Regeneron Pharmaceuticals position peaked at $2.09M in Q1 2020.
  • 932 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2020, filed 3 Aug 2020.